Skip to main content
TipRanks
Go Ultimate75% OFF

Radnet (PQIA) AI Stock Analysis

0 Followers
CH:PQIA

Radnet

(BX Swiss:PQIA)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Imaging Volume and Mix GrowthBroad-based procedure growth and a rising share of MRI, CT, and PET/CT indicate stronger utilization and a more valuable service mix. These trends can support revenue durability and operating leverage as RadNet expands capacity, centers, and advanced diagnostic capabilities.
Negative Factors
High Financial LeverageDebt remains substantial relative to equity, while recent losses make deleveraging more difficult. Elevated leverage can constrain capital allocation, increase sensitivity to operating setbacks, and reduce flexibility to fund centers, technology, acquisitions, or other strategic investments.

Radnet Business Overview & Revenue Model

Company Description

RadNet, Inc. operates as a prominent healthcare services company specializing in outpatient diagnostic imaging across the United States. Their comprehensive offerings span a broad spectrum of advanced imaging techniques, including magnetic resonance...

Radnet Earnings Call Summary

Earnings Call Date:Nov 08, 2026(Q3-2026)|Next Earnings Date:Mar 02, 2027
Earnings Call SentimentPositive

The call was strongly positive. RadNet reported record company revenue and adjusted EBITDA, broad-based imaging volume growth, expanding advanced-imaging mix, raised Imaging Center and Digital Health guidance, strong liquidity, substantial Digital Health bookings and ARR growth, and continued progress in AI deployment and the planned ONRAD acquisition. The main challenges were year-over-year Digital Health EBITDA and margin declines, labor shortages, implementation seasonality and constraints, and expected 2027 Medicare reimbursement pressure, but management characterized the implementation constraints as resolved and remained confident about fourth-quarter and 2027 growth.

Positive Updates

Record Third-Quarter Revenue and Adjusted EBITDA
Total company revenue reached a quarterly record of $638.3 million, up 22.1% from $522.9 million in last year's third quarter. Adjusted EBITDA also reached a quarterly record of $105 million, up 23.8% from $84.9 million, while adjusted EBITDA margin expanded 23 basis points to 16.5%. Adjusted diluted EPS increased to $0.30 from $0.24.

Negative Updates

Digital Health Adjusted EBITDA Declined Year Over Year
Digital Health adjusted EBITDA was $3 million, compared with $3.5 million in last year's third quarter. Management attributed the decline to continued investment in commercial and implementation headcount and temporary margin dilution from recent acquisitions, including GLEAMER.

Company Guidance

For 2026, Imaging Center segment total net revenue guidance is $2.385 billion to $2.435 billion, adjusted EBITDA guidance is $350 million to $363 million, capital expenditure guidance is $170 million to $180 million, and free cash flow guidance is $120 million to $130 million; Digital Health revenue guidance is $135 million to $145 million, while adjusted EBITDA guidance is $10 million to $13 million and adjusted EBITDA before noncapitalized R&D guidance is $11 million to $13 million, with Digital Health CapEx guidance increased by $1 million. Digital Health is on track for more than $140 million of ARR by year-end, roughly 87% growth over 2025, expects fourth quarter revenue to grow about 20% sequentially, and indicated a fully underpinned fourth quarter of well above $40 million; ONRAD is expected to add $190 million to $200 million of revenue and $60 million to $65 million of adjusted EBITDA in its first year of operation after closing. For 2027, RadNet estimated an approximately $5 million revenue impact from the final Medicare rule, while noting Congress may act to partially or fully reverse this reduction.

Radnet Risk Analysis

Radnet disclosed 48 risk factors in its most recent earnings report. Radnet reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.We will incur significant transaction and Merger-related costs in connection with the Mergers.Q3, 2026
2.Completion of the Mergers is subject to certain conditions and if these conditions are not satisfied, waived or fulfilled in a timely manner, the Mergers may be delayed or not completed.Q3, 2026
3.Our business relationships may be subject to disruption due to uncertainty associated with the Mergers.Q3, 2026

Radnet Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

CH:PQIA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
DGXDGX76Outperform$28.50B25.3715.21%1.31%9.13%17.93%
LHLH75Outperform$29.95B29.9211.54%0.78%6.02%19.63%
NEONEO60Neutral$1.95B-60.05-3.97%―11.08%71.76%
OPKOPK55Neutral$1.20B-8.13-12.41%―-21.87%18.50%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
NDRANDRA44Neutral$5.55M-0.68-150.38%――60.87%

* Healthcare Sector Average

Performance Comparison

-25%0%25%50%LHOPKDGXNEONDRADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
CH:PQIA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
LHLabcorp Holdings Inc.367.13104.4839.78%
OPKOpko Health1.570.2720.77%
DGXQuest Diagnostics258.2870.8537.80%
NEONeoGenomics Inc.14.823.2127.65%
NDRAEndra Life Sciences3.58-1.17-24.58%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.